ARIKAYCE KIT Drug Patent Profile

Which patents cover Arikayce Kit, and when can generic versions of Arikayce Kit launch?

Arikayce Kit is a drug marketed by Insmed Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has one hundred and fourteen patent family members in twenty-six countries.

The generic ingredient in ARIKAYCE KIT is amikacin sulfate. There are fifteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the amikacin sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Arikayce Kit

A generic version of ARIKAYCE KIT was approved as amikacin sulfate by MEITHEAL on September 28^th, 1993.

Summary for ARIKAYCE KIT

International Patents:	114
US Patents:	13
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARIKAYCE KIT

US Patents and Regulatory Information for ARIKAYCE KIT

ARIKAYCE KIT is protected by thirteen US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes			Y
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes

International Patents for ARIKAYCE KIT

See the table below for patents covering ARIKAYCE KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	2852391
South Korea	101358660
Slovenia	3142643
Hong Kong	1201749	包含用於治療肺部感染的氨基葡糖苷的脂質體 (LIPOSOMES COMPRISING AN AMINOGLYCOSIDE FOR THE TREATMENT OF PULMONARY INFECTIONS)
Japan	2015025016	抗感染剤の徐放 (SUSTAINED RELEASE OF ANTIINFECTIVES)
European Patent Office	3142643	MÉTHODES DE TRAITEMENT D'INFECTIONS PULMONAIRES MYCOBACTÉRIENNES NON-TUBERCULEUSES (METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS)

ARIKAYCE KIT Investment and Fundamentals Analysis

Last updated: February 20, 2026

What is ARIKAYCE KIT?

ARIKAYCE KIT is a combination medication used for treating Mycobacterium avium complex (MAC) lung disease in adult patients who do not respond to other treatments. The kit includes amikacin liposome inhalation suspension (ALIS) and related accessories for inhalation therapy. It is marketed by Insmed Incorporated.

Market Overview

The global MAC lung disease market is experiencing growth driven by increasing awareness, diagnostic advancements, and a rising prevalence of nontuberculous mycobacterial (NTM) infections.

Prevalence Data and Demographics

• Estimated 12,000–14,000 MAC cases annually in the U.S. (CDC, 2022).
• NTM lung disease prevalence has increased by 8% annually over the past decade (WHO, 2021).
• Patients are typically over 60 with comorbidities such as COPD or bronchiectasis.

Competitive Landscape

• Main competitor: Amikacin Inhale (Commercialized by Baxter).
• Other therapies: Azithromycin, Ethambutol, Rifampin as part of multi-drug regimens.
• No direct generic competition for ARIKAYCE, but pipeline drugs focus on alternative delivery systems or oral formulations.

Commercial Performance and Revenue Data

• 2022 revenue: ~$252 million, up 19% YoY (Insmed Annual Report, 2022).
• Peak sales forecast: $400–$600 million in North America by 2025, based on market penetration projections.
• Growth driven by expanded FDA approvals, increased physician adoption, and geographic expansion.

Regulatory Status and Approvals

• Approved by FDA in 2018 for refractory MAC lung disease.
• Approved in Japan in 2020.
• EMA Marketing Authorization Application under review, with potential approval in Europe in 2023.
• Regulatory challenges include potential for reimbursement delays and clinical trial requirements in new markets.

Investment Fundamentals

Revenue Drivers

• Expanded FDA label extensions increase eligible patient pool.
• Growing awareness and diagnosis rates expand market access.
• Reimbursement codes for inhaled antibiotics support hospital and outpatient adoption.

Cost Structure and Margins

• Manufacturing costs: Inhalation formulations involve complex liposomal delivery, asserting higher costs than traditional antibiotics.
• Margins: Estimated gross margin is approximately 70%, supported by high-value niche drug profile.
• R&D investments focus on pipeline development, including oral formulations and new indications.

Pipeline and Future Potential

• ARIKAYCE IV: Intravenous form in late-phase trials for cystic fibrosis-related indications.
• Novel formulations: Oral liposomal amikacin in early-stage studies.
• Additional indications: NTM disease in pediatric populations, non-tuberculous mycobacterial disease outside MAC.

Risks and Challenges

• Pricing pressure: Increasing scrutiny on drug pricing in the US and Europe.
• Patent expiration: Key patents expire between 2030 and 2035, with potential biosimilar entries.
• Clinical risks: Efficacy and safety data required for line extensions and new indications.
• Market penetration: Growing off-label use could strain healthcare resource allocation.

Key Market and Financial Metrics

Metric	Data	Source
2022 Revenue	$252 million	Insmed Annual Report
YoY Growth	19%	Insmed Annual Report
Estimated Market Size 2025	$400–$600 million	Market Research Firm Projections
Gross Margin	70%	Estimated from financials
Patent Expiry	2030–2035	Company Patent Filings

Strategic Considerations for Investors

• Evaluate pipeline progress and likelihood of new approvals.
• Monitor regulatory developments in international markets.
• Assess competitive threats, particularly generics and biosimilars.
• Consider reimbursement and healthcare policy changes influencing uptake.

Key Takeaways

• ARIKAYCE KIT holds a dominant position in a niche but expanding market.
• Revenue growth is supported by market expansion, though sustainability depends on pipeline success and patent protection.
• The drug's complex manufacturing translates into higher costs and margins but also potential supply chain risks.
• Regulatory and reimbursement landscapes influence future sales trajectory.
• The pipeline, including oral formulations, offers upside but carries clinical and regulatory risk.

FAQs

1. What patient population primarily drives ARIKAYCE KIT sales?
   Patients with refractory MAC lung disease, typically older adults with comorbid respiratory conditions.

2. What are the key risks for investing in ARIKAYCE KIT?
   Market competition, patent expiry, regulatory delays, and pricing pressures.

3. How does ARIKAYCE KIT compare with its competitors?
   It has a unique liposomal inhalation delivery recently approved for refractory MAC, with no direct generics yet.

4. What future growth avenues exist for ARIKAYCE KIT?
   Expansion to new geographic markets, new indications, and development of oral formulations.

5. When are patent protections expected to lapse?
   Between 2030 and 2035, depending on jurisdiction and patent filings.

---

References

[1] Centers for Disease Control and Prevention. (2022). Nontuberculous Mycobacteria (NTM) Infections. CDC.
[2] World Health Organization. (2021). Global antimicrobial resistance surveillance report. WHO.
[3] Insmed Incorporated. (2022). Annual Report.
[4] European Medicines Agency. (2022). Marketing Authorization Application Summary.
[5] Market Research Firm. (2022). Nontuberculous Mycobacteria Market Forecast.